Search

Your search keyword '"Musallam, Khaled M."' showing total 83 results

Search Constraints

Start Over You searched for: Author "Musallam, Khaled M." Remove constraint Author: "Musallam, Khaled M." Topic iron overload Remove constraint Topic: iron overload
83 results on '"Musallam, Khaled M."'

Search Results

1. Anemia and iron overload as prognostic markers of outcomes in β-thalassemia.

2. Revisiting iron overload status and change thresholds as predictors of mortality in transfusion-dependent β-thalassemia: a 10-year cohort study.

3. Αlpha-thalassemia: A practical overview.

4. How I treat non-transfusion-dependent β-thalassemia.

6. Risk of mortality from anemia and iron overload in nontransfusion-dependent β-thalassemia.

8. Long-term improvement in cardiac magnetic resonance in β-thalassemia major patients treated with deferasirox extends to patients with abnormal baseline cardiac function.

9. Ineffective Erythropoiesis: Anemia and Iron Overload.

10. Serum ferritin values between 300 and 800 ng/mL in nontransfusion-dependent thalassemia: A probability curve to guide clinical decision making when MRI is unavailable.

11. Iron overload across the spectrum of non-transfusion-dependent thalassaemias: role of erythropoiesis, splenectomy and transfusions.

12. One-year results from a prospective randomized trial comparing phlebotomy with deferasirox for the treatment of iron overload in pediatric patients with thalassemia major following curative stem cell transplantation.

13. Sustained improvements in myocardial T2* over 2 years in severely iron-overloaded patients with beta thalassemia major treated with deferasirox or deferoxamine.

15. Association between cardiac T2* magnetic resonance imaging values and endocrine function tests in patients with β-thalassemia major.

16. Deferiprone-induced seizures in a patient with β-thalassemia major.

17. Evaluation of the 5mg/g liver iron concentration threshold and its association with morbidity in patients with β-thalassemia intermedia.

18. Assessment and management of iron overload in β-thalassaemia major patients during the 21st century: a real-life experience from the Italian WEBTHAL project.

19. Iron overload in β-thalassemia intermedia: an emerging concern.

20. Treating iron overload in patients with non-transfusion-dependent thalassemia.

21. A liver mass in an iron-overloaded thalassaemia intermedia patient.

22. Longitudinal changes in serum ferritin levels correlate with measures of hepatic stiffness in transfusion-independent patients with β-thalassemia intermedia.

23. β-thalassemia intermedia: a clinical perspective.

24. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective.

25. Glomerular hyperfiltration and proteinuria in transfusion-independent patients with β-thalassemia intermedia.

26. Iron-chelating therapy for transfusional iron overload.

27. Iron in sickle-cell disease: what have we learned over the years?

28. Deferiprone or deferasirox for cardiac siderosis in beta-thalassemia major.

29. Iron chelation therapy for transfusional iron overload: a swift evolution.

30. Renal complications in transfusion-dependent beta thalassaemia.

31. Iron chelation therapy for patients with sickle cell disease and iron overload.

32. A computed tomography Iron Index.

33. Absence of cardiac siderosis despite hepatic iron overload in Italian patients with thalassemia intermedia: an MRI T2* study.

34. Iron overload indices rise linearly with transfusion rate in patients with sickle cell disease.

35. Magnetic resonance evaluation of hepatic and myocardial iron deposition in transfusion-independent thalassemia intermedia compared to regularly transfused thalassemia major patients.

36. Absence of cardiac siderosis by MRI T2* despite transfusion burden, hepatic and serum iron overload in Lebanese patients with sickle cell disease.

37. Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia.

38. Iron overload: consequences, assessment, and monitoring.

41. Differential effects of iron chelators on iron burden and long-term morbidity and mortality outcomes in a large cohort of transfusion-dependent β-thalassemia patients who remained on the same monotherapy over 10 years.

42. Random Forest Clustering Identifies Three Subgroups of β-Thalassemia with Distinct Clinical Severity.

43. Cross-Talk between Available Guidelines for the Management of Patients with Beta-Thalassemia Major.

44. Glomerular Hyperfiltration and Proteinuria in Transfusion-Independent Patients with β-Thalassemia Intermedia.

45. Current Strategies in the Assessment of Iron Overload.

46. Current Strategies in the Assessment of Iron Overload.

47. Age-related complications in treatment-naïve patients with thalassaemia intermedia.

48. Overview of Iron Chelation Therapy with Desferrioxamine and Deferiprone.

49. A killer revealed: 10-year experience with beta-thalassemia intermedia.

50. Iron overload in non-transfusion-dependent thalassemia.

Catalog

Books, media, physical & digital resources